Algorithm Sciences

Algorithm Sciences, Inc. is a biopharmaceutical company founded in 2019 that specializes in optimizing treatments for cardiovascular diseases. The company is focused on developing precision medicines, particularly for rare diseases. Their lead asset, PulmoProst, is a drug-device combination for treating Pulmonary Arterial Hypertension (PAH). This platform utilizes the Prometra II implantable infusion pump to continuously deliver a potent drug, IV iloprost, aiming to improve patient outcomes and quality of life.

In June 2023, Algorithm Sciences acquired all assets of Flowonix Medical, Inc., including the intellectual property and pre-market approval for the Prometra II pump. This acquisition was a strategic move to secure the supply chain for its lead candidate and reduce costs. Subsequently, in June 2024, the company established a majority-owned subsidiary, Infusyn Therapeutics, to manufacture and supply the Prometra II pump for its existing approved markets in chronic pain and spasticity. This restructuring allows Algorithm Sciences to focus on the clinical development of PulmoProst for PAH while Infusyn handles the commercialization of the pump technology.

The company is led by a team of experienced executives, including CEO Michael Tilton, and COO/CFO David Cavalier. Algorithm Sciences is backed by venture capital, with Laidlaw & Company being a key investor through its venture arm, Lucius Partners. The business model involves developing and gaining regulatory approval for its proprietary drug/device combinations. It also generates revenue through the sale of the Prometra II pump via its subsidiary and seeks partnerships to apply its precision delivery technology to other therapeutic areas.

Keywords: precision medicine, biopharmaceutical, cardiovascular diseases, rare diseases, Pulmonary Arterial Hypertension, PAH, drug-device combination, implantable infusion pump, Prometra II, Flowonix Medical, PulmoProst, iloprost, Laidlaw & Company, Lucius Partners, Infusyn Therapeutics, clinical development, drug delivery, specialty pharma